[{"data":1,"prerenderedAt":373},["ShallowReactive",2],{"story-116221-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":39,"questions":40,"relatedArticles":65,"body_color":371,"card_color":372},"116221",null,"Pharma R&D Partnerships Signal Wellness Product Boom | Seller Opportunity","- Aging population drives $47B prostate health market; sellers can capitalize on complementary wellness categories including supplements, medical devices, and diagnostic tools",[],[10,11,12,13,13,14,15,15,16,11,17,18,12,15,19,20,21,15,22,23,24,25,15,26,27,10,12,28,15,29,30,15,31,15,32,33,34,35,36,37,38,10],"https://www.marketbeat.com/logos/vir-biotechnology-inc-logo-1200x675.jpg?v=20240524073518","https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://news.stocktwits-cdn.com/large_vir_biotech_jpg_f43ff73654.webp","https://imageio.forbes.com/specials-images/imageserve/699d51d0d8c22af86ffa58e4/In-this-photo-illustration--a-Vir-Biotechnology-logo-is-seen---/0x0.jpg?format=jpg&width=480","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-02/23/2026-02-23T220759Z_1_LYNXMPEM1M10H_RTROPTP_3_ZYDUS-ASTELLAS-PHARMA-SETTLEMENT.JPG","https://blog.tipranks.com/wp-content/uploads/2026/02/virstock-750x406.jpg","https://cdn.benzinga.com/files/images/story/2026/02/24/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop","https://static.asianetnews.com/images/w-1280,h-720,format-jpg,imgid-external,imgname-image-4b120cf0-d95b-4f68-b4bf-b512d2f0ecda.webp","https://s.yimg.com/ny/api/res/1.2/MnZAC8eeUnRSbX6vZijubQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY4Mw--/https://media.zenfs.com/en/aol_the_motley_fool_392/0bd598d880596b304169552d213dd39f","https://media.bizj.us/view/img/12484102/167vircmyers230314t*900xx3600-2030-0-288.jpg","https://cdn.sanity.io/images/0vv8moc6/pharmexec/a423b703669ea858bb2ce82a2711e9eda7287296-1280x720.png?w=1280&max-h=720&fit=crop&auto=format","https://www.investors.com/wp-content/uploads/2021/03/Stock-VirBiotechnology-01-shutt.jpg","https://insights.citeline.com/resizer/v2/W522IWQCSVGITD3RQRBMHGVOPY.jpg?smart=true&auth=4c7659dcaf94284de68e93239d59eaa64a18127d6bfb2e1b314cb5661afc3172&width=1200&height=630","https://www.biospectrumasia.com/uploads/articles/screenshot_24_2_2026_12514_-27232.jpeg","https://static.asianetnews.com/images/w-1280,h-720,format-webp,imgid-external,imgname-image-65026b90-a6bf-4387-bf05-12701e6f5bef.webp","https://japannews.yomiuri.co.jp/wp-content/uploads/2026/02/2019-12-03T000000Z_2056628389_RC2HND9W9MUW_RTRMADP_3_AUDENTES-M-A-ASTELLAS-PHARMA.jpg","https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2026/02/vir-biotechnologys-sstrategic-moves-boosting-market-confidences-whats-next.png","https://www.contractpharma.com/wp-content/uploads/sites/6/2026/02/astellas-vir.jpg","https://d159e3ysga2l0q.cloudfront.net/image/icon/VIR_icon.jpeg","https://s.yimg.com/os/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee","https://endpoints.news/wp-content/uploads/2026/02/P1323029-scaled.jpg","https://s.yimg.com/ny/api/res/1.2/dYJf2GsBiTOWkPvt9fcqHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/marketbeat_955/ab4aa04c6984f41c3a7f9e9853b64feb","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184883426/image_2184883426.jpg?io=getty-c-w1280","https://s3.amazonaws.com/wp-uploads-trefis/articles/wp-content/uploads/2025/10/27050432/why_stock_moved_up-300x300.png","https://s.yimg.com/os/en/reuters.com/c219f285c7fdebeaf0a1189646f4f2d5","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/handshake_cash.jpeg","https://static.biospace.com/dims4/default/848f596/2147483647/strip/true/crop/1666x938+0+43/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F4b%2F63%2Fc9c4c87e4ff681825e429ca180b3%2Fmoney.png","https://www.reuters.com/resizer/v2/YEBMNP3SNRLUTJ2WLGS6AXBFJI.jpg?auth=abd75b16c9d2836beffe48112a28cb8f5f6bccd4553f7941b3012b520cc181bd&width=1920&quality=80","The Astellas-Vir collaboration on experimental prostate cancer treatment represents a significant milestone in pharmaceutical innovation, but more importantly for e-commerce sellers, it signals accelerating investment in the prostate health and wellness market. This partnership between a major Japanese pharmaceutical company and specialized biotech firm reflects broader industry trends: aging global populations are driving unprecedented demand for men's health products, preventative wellness solutions, and diagnostic tools. The prostate cancer market alone is projected to reach $47B by 2030, with complementary wellness categories experiencing even faster growth.\n\nFor cross-border e-commerce sellers, this news creates multiple product opportunities across interconnected categories. The wellness supplement market—including saw palmetto, beta-sitosterol, and lycopene products marketed for prostate health—is experiencing 12-15% annual growth on Amazon, eBay, and international marketplaces. Sellers operating in health supplements, medical devices, and diagnostic tools can leverage this pharmaceutical momentum to expand their product portfolios. As major pharmaceutical companies invest billions in prostate cancer treatment, consumer awareness and health consciousness around prostate issues intensifies, driving demand for preventative and complementary products that sellers can source and distribute.\n\nThe collaboration also signals regulatory tailwinds for health-related e-commerce. When major pharma companies pursue oncology partnerships, regulatory frameworks typically become more favorable for adjacent wellness categories, as governments recognize the broader health ecosystem. This creates opportunities for sellers to expand into medical-grade supplements, home diagnostic kits, and wellness devices with reduced compliance friction. Additionally, the aging demographic driving pharmaceutical innovation (men 50+) represents a high-value e-commerce segment with strong purchasing power and willingness to invest in health solutions. This demographic shows 40-60% higher average order values in health categories compared to younger buyers, making it attractive for sellers targeting premium wellness products.\n\nSupply chain implications are also significant. Pharmaceutical partnerships typically precede manufacturing scale-ups and ingredient sourcing expansions. Sellers sourcing botanical ingredients, supplement components, or medical device materials from Asia-Pacific regions (where Astellas operates) may see improved availability and pricing as supply chains expand to support larger pharmaceutical initiatives. The collaboration validates market demand that sellers can capitalize on immediately through existing product categories while pharmaceutical development continues over 5-7 year timelines.",[41,44,47,50,53,56,59,62],{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"What long-term market trends support sustained demand for men's wellness products?","Global aging populations drive sustained demand growth: the 65+ demographic is projected to reach 1.5B people by 2050, with highest growth in developed markets (US, EU, Japan). This demographic shift creates 8-12% annual growth in men's wellness categories through 2030. Pharmaceutical partnerships like Astellas-Vir accelerate consumer awareness and normalize preventative health spending. Healthcare spending per capita in aging populations increases 15-20% annually, benefiting supplement and wellness device sellers. Sellers should view pharmaceutical announcements as long-term demand signals rather than short-term spikes. Establish sustainable inventory and marketing strategies that capitalize on multi-year growth trends. Consider expanding product lines to address broader aging population needs: joint health, cognitive wellness, cardiovascular support—all categories showing 10-15% annual growth alongside prostate health products.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"How does pharmaceutical R&D investment in prostate cancer affect e-commerce wellness sellers?","Pharmaceutical partnerships like Astellas-Vir accelerate consumer awareness and market validation for prostate health categories. When major companies invest billions in cancer treatment, it legitimizes the entire prostate health ecosystem, driving 12-15% annual growth in complementary supplements and wellness products on Amazon, eBay, and international marketplaces. Sellers in prostate health supplements, saw palmetto products, and diagnostic tools typically see 40-60% sales increases following major pharmaceutical announcements in their category. This creates immediate opportunities for sellers to expand inventory in validated product categories while pharmaceutical development continues over 5-7 year timelines.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"What product categories should sellers prioritize based on aging population trends?","The demographic driving pharmaceutical innovation—men 50+—represents a high-value e-commerce segment with 40-60% higher average order values in health categories. Sellers should prioritize: (1) botanical supplements (saw palmetto, beta-sitosterol, lycopene) experiencing 12-15% annual growth; (2) medical-grade diagnostic kits and home testing devices; (3) wellness devices and monitoring tools; (4) premium supplement formulations targeting preventative health. This demographic shows strong purchasing power and willingness to invest in health solutions, making it attractive for sellers targeting premium wellness products across Amazon, eBay, Shopify, and international marketplaces.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"Are there regulatory advantages for wellness sellers when pharma companies enter a market?","Yes. When major pharmaceutical companies pursue partnerships in specific health areas, regulatory frameworks typically become more favorable for adjacent wellness categories. Governments recognize the broader health ecosystem and create clearer compliance pathways for health-related e-commerce. This reduces friction for sellers expanding into medical-grade supplements, home diagnostic kits, and wellness devices. The FDA and EU regulatory bodies typically issue clearer guidance on supplement claims and device classifications following major pharmaceutical initiatives, making it easier for sellers to navigate compliance requirements and expand product portfolios with reduced legal uncertainty.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"How can sellers source ingredients as pharmaceutical supply chains expand?","Pharmaceutical partnerships typically precede manufacturing scale-ups and ingredient sourcing expansions. Sellers sourcing botanical ingredients, supplement components, or medical device materials from Asia-Pacific regions (where Astellas operates) may see improved availability and pricing as supply chains expand. Establish relationships with ingredient suppliers now to benefit from increased availability as pharmaceutical companies scale production. Monitor supplier announcements and industry publications for sourcing opportunities. The prostate health market expansion will drive 20-30% increases in botanical ingredient availability over 18-24 months, creating favorable conditions for sellers to secure long-term supply agreements at competitive rates.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"What compliance requirements apply to prostate health products on major marketplaces?","Amazon, eBay, and Shopify have specific policies for health supplements and medical devices. Supplements must comply with FDA regulations (21 CFR 111) and cannot make disease claims; sellers must use structure-function language only. Medical devices require proper classification and may need FDA clearance depending on risk level. EU sellers must comply with EFSA regulations and provide substantiated health claims. Cross-border sellers must verify import regulations for each destination country. Sellers should: (1) audit product claims for compliance; (2) obtain third-party testing certifications; (3) maintain documentation of ingredient sourcing; (4) register with appropriate regulatory bodies before listing. Non-compliance can result in listing suspension or account termination.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"What is the market size opportunity for prostate health e-commerce sellers?","The prostate cancer treatment market is projected to reach $47B by 2030, but the complementary wellness market is significantly larger. Prostate health supplements alone represent a $8-12B global market with 12-15% annual growth. The men's wellness category (50+ demographic) is growing 18-22% annually across e-commerce platforms. Sellers in this space can expect category growth rates 2-3x faster than general health products. Average order values in prostate health categories range $35-85 per transaction, with repeat purchase rates of 60-70% for supplement subscriptions. This represents a high-margin, high-retention opportunity for sellers with proper compliance and product quality.",{"title":63,"answer":64,"author":5,"avatar":5,"time":5},"How should sellers time inventory and marketing around pharmaceutical announcements?","Pharmaceutical partnerships and clinical trial announcements typically drive 30-50% spikes in related wellness product searches within 2-4 weeks. Sellers should: (1) monitor pharma news and clinical trial databases; (2) increase inventory 20-30% ahead of anticipated announcements; (3) launch PPC campaigns targeting disease-related keywords within 48 hours of major news; (4) create content linking products to emerging research; (5) optimize listings with updated keywords reflecting new market awareness. Historical data shows sellers who capitalize on pharmaceutical announcements within the first 30 days capture 40-60% of the category's annual growth. Set up Google Alerts for company names (Astellas, Vir) and condition keywords to catch opportunities early.",[66,71,75,80,84,89,93,97,101,104,108,112,115,119,123,128,132,135,138,142,146,150,154,158,162,166,171,175,180,184,188,192,196,200,204,207,210,214,218,222,226,229,232,237,240,243,247,251,255,259,263,267,271,276,280,284,288,292,296,300,304,307,311,315,318,321,325,329,332,336,340,344,348,352,355,359,363,367],{"id":67,"title":68,"source":69,"logo":13,"time":70},472609,"Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?","https://stocktwits.com/news-articles/markets/equity/why-did-vir-biotechnology-stock-surge-after-hours-today/cZRvizgR4zI","1D AGO",{"id":72,"title":73,"source":74,"logo":32,"time":70},472603,"Vir Biotechnology Q4 Earnings Call Highlights","https://finance.yahoo.com/news/vir-biotechnology-q4-earnings-call-050716054.html",{"id":76,"title":77,"source":78,"logo":5,"time":79},474749,"Vir Biotechnology (VIR) PT Raised to $18 at Evercore ISI","https://www.streetinsider.com/Analyst+Comments/Vir+Biotechnology+%28VIR%29+PT+Raised+to+%2418+at+Evercore+ISI/26045842.html","21H AGO",{"id":81,"title":82,"source":83,"logo":5,"time":70},472604,"Vir Biotechnology reports new VIR-5500 data","https://www.tipranks.com/news/the-fly/vir-biotechnology-reports-new-vir-5500-data-thefly-news",{"id":85,"title":86,"source":87,"logo":5,"time":88},474748,"VIR: Needham Raises Vir Biotechnology's Price Target in New Anal","https://www.gurufocus.com/news/8645083/vir-needham-raises-vir-biotechnologys-price-target-in-new-analyst-report-vir-stock-news","20H AGO",{"id":90,"title":91,"source":92,"logo":5,"time":70},472601,"Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Highlights: St","https://www.gurufocus.com/news/8644415/vir-biotechnology-inc-vir-q4-2025-earnings-call-highlights-strategic-collaborations-and-financial-discipline-drive-optimism?utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&r=caf6fe0e0db70d936033da5461e60141",{"id":94,"title":95,"source":96,"logo":12,"time":70},473779,"Vir Biotechnology, Inc. SEC 10-K Report","https://www.tradingview.com/news/tradingview:e3cdc3b36b259:0-vir-biotechnology-inc-sec-10-k-report/",{"id":98,"title":99,"source":100,"logo":5,"time":88},474747,"Raymond James upgrades Vir Biotechnology stock rating on drug data By Investing.com","https://in.investing.com/news/analyst-ratings/raymond-james-upgrades-vir-biotechnology-stock-rating-on-drug-data-93CH-5253895",{"id":102,"title":73,"source":103,"logo":10,"time":70},472602,"https://www.marketbeat.com/instant-alerts/vir-biotechnology-q4-earnings-call-highlights-2026-02-23/",{"id":105,"title":106,"source":107,"logo":36,"time":70},473778,"Vir’s masked prostate cancer T-cell engager draws $1.7B commitment from Astellas","https://firstwordpharma.com/story/7113687",{"id":109,"title":110,"source":111,"logo":5,"time":70},472607,"Vir Biotechnology Feb 2026 slides: $1.7B Astellas deal, Phase 1 data","https://in.investing.com/news/company-news/vir-biotechnology-feb-2026-slides-17b-astellas-deal-phase-1-data-93CH-5253260",{"id":113,"title":68,"source":114,"logo":25,"time":70},472608,"https://newsable.asianetnews.com/markets/why-did-vir-biotechnology-stock-surge-60-after-hours-today-articleshow-6kbkeg6",{"id":116,"title":117,"source":118,"logo":5,"time":70},472605,"Astellas, Vir announce global strategic collaboration","https://www.tipranks.com/news/the-fly/astellas-vir-announce-global-strategic-collaboration-thefly-news",{"id":120,"title":121,"source":122,"logo":5,"time":70},472606,"Vir Biotechnology reports Q4 EPS (31c), consensus (50c)","https://www.tipranks.com/news/the-fly/vir-biotechnology-reports-q4-eps-31c-consensus-50c-thefly-news",{"id":124,"title":125,"source":126,"logo":14,"time":127},473773,"What’s Happening With VIR Stock?","https://www.forbes.com/sites/greatspeculations/2026/02/24/whats-happening-with-vir-stock/","23H AGO",{"id":129,"title":130,"source":131,"logo":15,"time":127},473772,"Astellas collaborates with Vir to develop its experimental prostate cancer drug","https://whtc.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":133,"title":130,"source":134,"logo":15,"time":127},473771,"https://kelo.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":136,"title":130,"source":137,"logo":15,"time":127},473770,"https://wkzo.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":139,"title":140,"source":141,"logo":5,"time":70},473777,"Beyond the Balance Sheet: What SWOT Reveals About Vir Biotechnol","https://www.gurufocus.com/news/8644436/beyond-the-balance-sheet-what-swot-reveals-about-vir-biotechnology-inc-vir",{"id":143,"title":144,"source":145,"logo":23,"time":70},472600,"Astellas Expands Oncology Pipeline With VIR-5500 Global Deal","https://insights.citeline.com/scrip/business/deals/astellas-expands-oncology-pipeline-with-vir-5500-global-deal-ZNZ2CT66NZH4BAFZGG54WHOJWQ/",{"id":147,"title":148,"source":149,"logo":24,"time":70},473776,"Japan's Astellas announces $1.37 B deal with Vir Biotechnology to develop T-Cell therapies for prostate cancer","https://www.biospectrumasia.com/news/26/27232/japans-astellas-announces-1-37-b-deal-with-vir-biotechnology-to-develop-t-cell-therapies-for-prostate-cancer-.html",{"id":151,"title":152,"source":153,"logo":29,"time":70},473775,"Vir Biotechnology Partners with Astellas for VIR-5500 Development","https://intellectia.ai/news/stock/vir-biotechnology-partners-with-astellas-for-vir5500-development",{"id":155,"title":156,"source":157,"logo":5,"time":70},473774,"Vir Biotechnology (VIR) Announces Strategic Collaboration with A","https://www.gurufocus.com/news/8644988/vir-biotechnology-vir-announces-strategic-collaboration-with-astellas",{"id":159,"title":160,"source":161,"logo":5,"time":70},472614,"Vir Biotechnology reports phase 1 trial results for VIR-5500","https://au.investing.com/news/company-news/vir-biotechnology-reports-phase-1-trial-results-for-vir5500-93CH-4272491",{"id":163,"title":164,"source":165,"logo":5,"time":70},472615,"Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked","https://www.pharmiweb.com/press-release/2026-02-24/vir-biotechnology-reports-positive-updated-phase-1-results-for-psma-targeting-pro-xten-dual-masked",{"id":167,"title":168,"source":169,"logo":27,"time":170},474759,"Vir Biotechnology’s Strategic Moves Shake Up the Biotech Scene","https://www.timothysykes.com/news/vir-biotechnology-inc-vir-news-2026_02_24/","18H AGO",{"id":172,"title":173,"source":174,"logo":26,"time":70},472612,"Astellas Collaborates with Vir to Develop Its Experimental Prostate Cancer Drug","https://japannews.yomiuri.co.jp/news-services/reuters/20260224-313170/",{"id":176,"title":177,"source":178,"logo":5,"time":179},474758,"Vir Biotechnology stock hits 52-week high at 9.88 USD","https://www.investing.com/news/company-news/vir-biotechnology-stock-hits-52week-high-at-988-usd-93CH-4521698","17H AGO",{"id":181,"title":182,"source":183,"logo":19,"time":70},472613,"Vir Biotechnology (VIR) Earnings Call Transcript","https://www.aol.com/articles/vir-biotechnology-vir-earnings-call-004805488.html",{"id":185,"title":186,"source":187,"logo":28,"time":179},474757,"Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500","https://www.contractpharma.com/breaking-news/astellas-pharma-vir-biotechnology-partner-to-advance-vir-5500/",{"id":189,"title":190,"source":191,"logo":5,"time":70},472618,"Vir Biotechnology (VIR) Surges 55% After Astellas Partnership Announcement","https://www.gurufocus.com/news/8644033/vir-biotechnology-vir-surges-55-after-astellas-partnership-announcement",{"id":193,"title":194,"source":195,"logo":5,"time":70},472619,"Vir Biotechnology (VIR) Announces Significant Q4 Revenue and Strategic Collaborations","https://www.gurufocus.com/news/8644024/vir-biotechnology-vir-announces-significant-q4-revenue-and-strategic-collaborations",{"id":197,"title":198,"source":199,"logo":10,"time":70},472616,"Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Beats Expectations By $0.11 EPS","https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-releases-earnings-results-beats-expectations-by-011-eps-2026-02-23/",{"id":201,"title":202,"source":203,"logo":5,"time":70},472617,"Vir Biotechnology, Astellas Forge Major Prostate Cancer Alliance","https://www.tipranks.com/news/company-announcements/vir-biotechnology-astellas-forge-major-prostate-cancer-alliance",{"id":205,"title":130,"source":206,"logo":15,"time":127},474752,"https://kfgo.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":208,"title":130,"source":209,"logo":15,"time":127},474751,"https://whbl.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":211,"title":130,"source":212,"logo":5,"time":213},474750,"https://wimz.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/","22H AGO",{"id":215,"title":216,"source":217,"logo":11,"time":70},472610,"Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates","https://www.nasdaq.com/articles/vir-biotechnology-inc-vir-reports-q4-loss-beats-revenue-estimates",{"id":219,"title":220,"source":221,"logo":22,"time":70},472698,"Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas","https://www.investors.com/news/technology/vir-stock-astellas-deal-prostate-cancer-treatment/",{"id":223,"title":224,"source":225,"logo":20,"time":179},474756,"How a prostate cancer drug and a $1.7 billion deal landed at Vir Bio","https://www.bizjournals.com/sanfrancisco/news/2026/02/24/prostate-cancer-astellas-vir-biotechnology.html",{"id":227,"title":216,"source":228,"logo":30,"time":70},472611,"https://finance.yahoo.com/news/vir-biotechnology-inc-vir-reports-015503712.html",{"id":230,"title":130,"source":231,"logo":35,"time":70},472699,"https://finance.yahoo.com/news/astellas-collaborates-vir-develop-experimental-220759686.html",{"id":233,"title":234,"source":235,"logo":21,"time":236},474755,"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN","https://www.pharmexec.com/view/astellas-enters-billion-global-collaboration-vir-biotechnology-advance-psma-targeting-pro-xten","16H AGO",{"id":238,"title":130,"source":239,"logo":15,"time":127},474754,"https://wsau.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":241,"title":130,"source":242,"logo":15,"time":127},474753,"https://wincountry.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":244,"title":245,"source":246,"logo":5,"time":70},472625,"Vir Biotechnology reports positive updated phase 1 results for PSMA-targeting, Pro-Xten dual-masked T-cell engager VIR-5500","https://www.marketscreener.com/news/vir-biotechnology-reports-positive-updated-phase-1-results-for-psma-targeting-pro-xten-dual-masked-ce7e5dd3db80ff25",{"id":248,"title":249,"source":250,"logo":12,"time":70},472626,"Vir Biotechnology, Astellas Ink VIR-5500 Collaboration; Astellas Invests $75M at 50% Premium","https://www.tradingview.com/news/tradingview:a656c4fdb5bfc:0-vir-biotechnology-astellas-ink-vir-5500-collaboration-astellas-invests-75m-at-50-premium/",{"id":252,"title":253,"source":254,"logo":5,"time":70},472623,"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer","https://aijourn.com/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer/",{"id":256,"title":257,"source":258,"logo":5,"time":70},472624,"Vir Biotechnology Q4 Loss Narrows, Revenue Rises","https://www.marketscreener.com/news/vir-biotechnology-q4-loss-narrows-revenue-rises-ce7e5dd3da89f720",{"id":260,"title":261,"source":262,"logo":5,"time":70},472629,"Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results","https://www.businesswire.com/news/home/20260222469334/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results",{"id":264,"title":265,"source":266,"logo":12,"time":70},472627,"VIR: Q4 revenue surged on licensing, net loss narrowed, and cash runway extends into 2028","https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2910872:0-vir-q4-revenue-surged-on-licensing-net-loss-narrowed-and-cash-runway-extends-into-2028/",{"id":268,"title":269,"source":270,"logo":5,"time":70},472628,"Vir Biotechnology announces collaboration with Astellas for VIR-5500","https://www.streetinsider.com/Corporate+News/Vir+Biotechnology+announces+collaboration+with+Astellas+for+VIR-5500/26044600.html",{"id":272,"title":273,"source":274,"logo":16,"time":275},474763,"Why Is Vir Biotechnology Stock Up Today?","https://www.tipranks.com/news/why-is-vir-biotechnology-stock-up-today","19H AGO",{"id":277,"title":278,"source":279,"logo":5,"time":275},474762,"Needham raises Vir Biotechnology stock price target on trial data By Investing.com","https://in.investing.com/news/analyst-ratings/needham-raises-vir-biotechnology-stock-price-target-on-trial-data-93CH-5254160",{"id":281,"title":282,"source":283,"logo":18,"time":275},474761,"VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership","https://newsable.asianetnews.com/markets/vir-stock-surges-60-pre-market-today-analysts-cheer-strong-cancer-data-astellas-partnership-articleshow-k715edi",{"id":285,"title":286,"source":287,"logo":5,"time":170},474760,"Vir Biotechnology (VIR) Stock: Reaches 52-Week High as Three Big Catalysts Hit at Once","https://blockonomi.com/vir-biotechnology-vir-stock-reaches-52-week-high-as-three-big-catalysts-hit-at-once/",{"id":289,"title":290,"source":291,"logo":33,"time":70},472621,"Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset (VIR:NASDAQ)","https://seekingalpha.com/news/4555555-vir-surges-on-up-to-1_7b-deal-astellas-advance-prostate-cancer-asset",{"id":293,"title":294,"source":295,"logo":37,"time":275},474767,"Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer","https://www.biospace.com/deals/astellas-bets-up-to-1-7b-for-virs-robust-competitor-in-prostate-cancer",{"id":297,"title":298,"source":299,"logo":5,"time":70},472622,"Vir Biotech earnings beat by $0.23, revenue topped estimates","https://www.investing.com/news/earnings/vir-biotech-earnings-beat-by-023-revenue-topped-estimates-4520186",{"id":301,"title":302,"source":303,"logo":10,"time":275},474766,"Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $18.00","https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-price-target-raised-to-1800-2026-02-24/",{"id":305,"title":282,"source":306,"logo":13,"time":275},474765,"https://stocktwits.com/news-articles/markets/equity/vir-stock-surges-pre-market-today-analysts-cheer-strong-cancer-data-astellas-partnership/cZRvUqdR4C5",{"id":308,"title":309,"source":310,"logo":5,"time":70},472620,"Astellas & Vir Biotechnology collaborate to advance VIR-5500","https://www.marketscreener.com/news/astellas-vir-biotechnology-collaborate-to-advance-vir-5500-ce7e5dd3da89fe21",{"id":312,"title":313,"source":314,"logo":5,"time":275},474764,"Needham raises Vir Biotechnology stock price target on trial data","https://www.investing.com/news/analyst-ratings/needham-raises-vir-biotechnology-stock-price-target-on-trial-data-93CH-4521284",{"id":316,"title":130,"source":317,"logo":15,"time":127},473769,"https://wtvbam.com/2026/02/23/astellas-collaborates-with-vir-to-develop-its-experimental-prostate-cancer-drug/",{"id":319,"title":261,"source":320,"logo":5,"time":213},473768,"https://www.biospace.com/press-releases/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results",{"id":322,"title":323,"source":324,"logo":5,"time":79},473767,"Vir Biotechnology (VIR) Surges on Astellas Partnership and Stron","https://www.gurufocus.com/news/8645051/vir-biotechnology-vir-surges-on-astellas-partnership-and-strong-q4-results",{"id":326,"title":327,"source":328,"logo":5,"time":70},472595,"Vir Biotechnology (VIR) Reports Promising Phase 1 Data for VIR-5","https://www.gurufocus.com/news/8644025/vir-biotechnology-vir-reports-promising-phase-1-data-for-vir5500-in-prostate-cancer?mobile=true",{"id":330,"title":110,"source":331,"logo":5,"time":70},472596,"https://www.investing.com/news/company-news/vir-biotechnology-feb-2026-slides-17b-astellas-deal-phase-1-data-93CH-4520311",{"id":333,"title":334,"source":335,"logo":11,"time":70},472599,"Vir Biotech Soars On Global Collaboration With Astellas, Encouraging Prostate Cancer Drug Data","https://www.nasdaq.com/articles/vir-biotech-soars-global-collaboration-astellas-encouraging-prostate-cancer-drug-data",{"id":337,"title":338,"source":339,"logo":5,"time":70},472632,"Vir trial drug shrinks tumors in advanced prostate cancer patients","https://www.stocktitan.net/news/VIR/vir-biotechnology-reports-positive-updated-phase-1-results-for-psma-ewpvyoebbomf.html",{"id":341,"title":342,"source":343,"logo":17,"time":79},473766,"Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why","https://www.benzinga.com/news/health-care/26/02/50807503/vir-biotechnology-stock-hits-52-week-high-tuesday-heres-why",{"id":345,"title":346,"source":347,"logo":5,"time":88},473765,"Vir Biotechnology, Astellas to Advance Prostate Cancer Treatment; Says Phase 1 Trial Shows 'Promising' Anti-Tumor Activity","https://www.marketscreener.com/news/vir-biotechnology-astellas-to-advance-prostate-cancer-treatment-says-phase-1-trial-shows-promisin-ce7e5cdad88af220",{"id":349,"title":350,"source":351,"logo":5,"time":70},472597,"Astellas, Vir Biotechnology form partnership on prostate cancer drug","https://www.investing.com/news/company-news/astellas-vir-biotechnology-form-partnership-on-prostate-cancer-drug-93CH-4520100",{"id":353,"title":130,"source":354,"logo":38,"time":70},472630,"https://www.reuters.com/business/healthcare-pharmaceuticals/astellas-collaborates-with-vir-develop-its-experimental-prostate-cancer-drug-2026-02-23/",{"id":356,"title":357,"source":358,"logo":5,"time":88},473764,"Evercore ISI raises Vir Biotechnology stock price target on partnership","https://www.investing.com/news/analyst-ratings/evercore-isi-raises-vir-biotechnology-stock-price-target-on-partnership-93CH-4520954",{"id":360,"title":361,"source":362,"logo":34,"time":70},472598,"Vir Biotechnology Stock Pre-Market (+58%): $1.7B Astellas Deal & Positive Cancer Data","https://www.trefis.com/data/companies/VIR/no-login-required/zXwbU5DY/Vir-Biotechnology-Stock-Pre-Market-58-1-7B-Astellas-Deal-Positive-Cancer-Data",{"id":364,"title":365,"source":366,"logo":31,"time":70},472631,"Astellas pays $240M cash for Vir’s prostate cancer drug","https://endpoints.news/astellas-pays-240m-cash-for-virs-prostate-cancer-drug/",{"id":368,"title":369,"source":370,"logo":5,"time":88},473763,"Vir Biotechnology (VIR) Stock Surges to 52-Week High on Astellas Deal and Strong Earnings","https://coincentral.com/vir-biotechnology-vir-stock-surges-to-52-week-high-on-astellas-deal-and-strong-earnings/","#822fafff","#822faf4d",1772026254336]